Akebia gets Nasdaq deficiency letter as stock closes below $1.00 for 30 straight days

Akebia Therapeutics, Inc.

• Nasdaq Listing Qualifications notified Akebia on October 21, 2026 that its bid price closed under $1.00 for 30 consecutive business days, breaching Rule 5550(a)(2).
• Akebia has until April 19, 2027 (180 calendar days) to regain compliance by holding a closing bid of at least $1.00 for 10 straight business days.
• If it fails, Akebia could get a second 180-day period by meeting market-value and other initial listing standards and signaling a reverse split if needed.
• The notice has no immediate effect on listing; Akebia said it will monitor its bid price and may pursue a reverse stock split, with no assurance of regaining compliance.
• CEO John P. Butler signed the filing dated October 23, 2026; continued failure could lead to a Staff delisting determination and appeal to a Nasdaq Hearings Panel.